Product Description: Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis[1].
Formula: N/A
References: [1]Schreiber AR, et al. Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Clin Cancer Drugs. 2018;5(1):42-49. /[2]Teng S W, et al. Using pharmacokinetic/efficacy modeling to identify the optimal schedule for MLN0264, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate, in a range of xenograft models[J]. Cancer Research, 2014, 74(19_Supplement): 4649-4649.
CAS Number: 1514889-12-3
Molecular Weight: N/A
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Antibody-Drug Conjugates (ADCs);Apoptosis;Guanylate Cyclase
English
Deutsch
